Sienna is developing a diversified topical biotech pipeline via its Topical by DesignTM platform and a photoparticle therapy platform. Its lead assets include SNA-120 (a TrkA inhibitor) in Phase IIb for pruritus and psoriasis, and SNA-125 (a dual TrkA/JAK3 inhibitor) in proof-of-concept for atopic dermatitis, psoriasis and pruritus. Through its photoparticle platform the company is advancing SNA-001 in pivotal trials for acne vulgaris and for permanent reduction of unwanted light-pigmented hair. The company is clinical-stage and privately held, led by experienced scientists, clinicians and business leaders in dermatology and aesthetics. Sienna intends to use the proceeds from the financing to advance programs spanning pivotal clinical trials to preclinical programs. The company is based in Westlake Village, Calif. Sienna Biopharmaceuticals is a clinical-stage company focused on medical dermatology and aesthetics and developing products based on its Silver Plasmonic Therapy (SPT) technology. SPT uses a proprietary topical solution containing patented plasmonic particles that interact with medical laser systems to target microstructures in the skin; clinical trials are already underway. The company is evaluating indications including acne and permanent hair removal and is exploring additional potential uses. Management says the additional capital will be used to fund pharmaceutical research and advance business development efforts. Sienna has raised approximately $46 million in capital to date following a $12 million second closing of its Series A. Its executive team includes leaders from Kythera Biopharmaceuticals, led by President and CEO Frederick C. Beddingfield III, MD, PhD, and Executive Chairman Keith Leonard, and the team reports experience across more than 75 aesthetic and medical dermatology products and over 100 international regulatory filings and approvals. Sienna Biopharmaceuticals is a development-stage company focused on discovery, clinical development, and commercialization of novel aesthetics and medical dermatology products. Its lead proprietary technology, Silver Plasmonic Therapy (SPT), uses a topical solution of patented plasmonic particles that interact with medical laser systems to target microstructures in the skin. SPT has promising applications in acne and permanent hair removal; clinical trials are already underway and the company is evaluating additional indications. The company emphasizes building a pipeline of early- to late-stage novel assets and intends to advance its SPT technology into further development. Management and the executive team bring leadership and experience from Kythera and have participated in development or commercialization of many leading global dermatology and aesthetics brands. Financially, Sienna completed a $34 million Series A financing to support its development efforts.

Total raised

$86M

Funding rounds

3

Latest round

Series B

Latest activity

Apr 2017